For Prelims: National Pharmaceutical Pricing Authority (NPPA), Drugs (Prices Control) Order (DPCO), Trade Margin, Maximum Retail Price (MRP), Full form of NPPA, Parent Ministry of NPPA, Number of drug brands revised, Effective date for new prices
For Mains: Financial toxicity; Catastrophic health expenditure; Trade Margin Rationalisation (TMR) vs Cost-based pricing; Accessibility vs Affordability of medicines
Source:
Why in the news?
This exposes past excessive pricing practices and highlights the need for stronger, permanent price control mechanisms to make life-saving cancer treatment affordable based on medical need, not a patient's ability to pay.
Summary
- NPPA released revised MRPs for 543 brands of anti-cancer medicines, effective from 9 November 2026, based on Trade Margin Rationalisation (TMR) of 137 non-scheduled drugs.
- Price cuts are drastic (e.g., palbociclib from ₹40,421 to ₹2,720 per pack), exposing excessive past pricing and profiteering in the pharmaceutical supply chain.
- Health experts argue TMR policy is insufficient and flawed; they advocate for cost-based price control, permanent margin caps, and complementary measures like wider insurance coverage.
Highlights
Drastic Price Cuts
NPPA slashed MRPs for 543 anti-cancer drug brands, with some prices falling by over 90%, exposing historical excessive pricing.
Policy Intervention
The price revision follows Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs to improve affordability and access.
Insufficient Measure
Experts argue TMR is flawed and call for cost-based price control, permanent margin caps, and complementary measures like insurance expansion.
Context / Background
Cancer treatment in India has long been associated with catastrophic out-of-pocket expenditure, pushing families into poverty. The National Pharmaceutical Pricing Authority (NPPA), under the Drugs (Prices Control) Order (DPCO), regulates prices of scheduled (essential) drugs. However, many newer, patented, and non-scheduled cancer drugs remained outside strict price control, leading to allegations of excessive trade margins and profiteering by manufacturers and distributors.
Core Analysis & Implications
The sharp price cuts (e.g., ~93% for palbociclib) validate concerns about inflated pricing. The Trade Margin Rationalisation (TMR) policy caps the margin between Price to Stockist (PTS) and MRP. However, critics like Jan Swasthya Abhiyan highlight its flaws: it allows a high 42.8% markup, excludes drugs under Patient Assistance Programs, and relies on self-reporting by companies. This exposes weaknesses in India's drug pricing policy, which often reacts to public outrage rather than implementing a robust, transparent cost-based formula. The move will reduce immediate financial toxicity for patients but needs stronger enforcement.
Future Outlook / Way Forward
For sustainable affordability, a multi-pronged approach is needed: 1) Strengthening NPPA's mandate for cost-based pricing and permanent margin caps for all essential drugs. 2) Expanding and streamlining government health insurance (Ayushman Bharat) and reimbursement schemes to cover expensive therapies. 3) Promoting quality generic and biosimilar manufacturing through production-linked incentive (PLI) schemes. 4) Ensuring robust monitoring of the supply chain to prevent price re-escalation. 5) Integrating price control with broader health system strengthening for comprehensive cancer care.
Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An independent regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It was established in 1997 to fix and revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of medicines under the Drugs (Prices Control) Order (DPCO).
- Drugs (Prices Control) Order (DPCO)
- An order issued by the Government of India under Section 3 of the Essential Commodities Act, 1955, to regulate the prices of essential and life-saving medicines. It categorizes drugs into 'scheduled' (price-controlled) and 'non-scheduled' categories.
- Trade Margin
- The difference between the price at which a manufacturer sells to a stockist (Price to Stockist or PTS) and the Maximum Retail Price (MRP) paid by the consumer. Rationalising this margin is a tool to reduce MRP without directly controlling the manufacturer's price.
- Maximum Retail Price (MRP)
- The highest price at which a product can be sold to the end consumer. It is inclusive of all taxes. As per law, no retailer can charge a price above the MRP printed on the product.
Facts to remember
Tap a card to see the answer. Try to recall it first.
How exams will ask this
- Data: 543 brands of anti-cancer drugs had MRP revised; effective date is 9 November 2026.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Policy: Trade Margin Rationalisation (TMR) applied to 137 non-scheduled anti-cancer drugs.
Don't make this mistake!
They may ask about the parent ministry of NPPA (Chemicals & Fertilizers, not Health & Family Welfare). They might confuse 'scheduled' vs 'non-scheduled' drugs under DPCO or swap the number of drugs (137 vs 543). Another trap is asking about the legal basis (DPCO under Essential Commodities Act, not the Drugs and Cosmetics Act).
Write these in mains answers
- Financial toxicity
- Catastrophic health expenditure
- Trade Margin Rationalisation (TMR) vs Cost-based pricing
- Accessibility vs Affordability of medicines
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
The National Pharmaceutical Pricing Authority (NPPA) operates under which Union Ministry?
Explanation: The NPPA is an independent body under the Department of Pharmaceuticals, which falls under the Ministry of Chemicals and Fertilizers. This is a key static GK fact often tested.
- Q2Hard
Consider the following statements regarding the recent news on cancer drug prices:
- 1.The National Pharmaceutical Pricing Authority revised MRPs for 543 brands of anti-cancer medicines.
- 2.The new prices are based on the Trade Margin Rationalisation applied to scheduled formulations under the DPCO.
- 3.The revised price list will be effective from 9th November 2026.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct as per the article. Statement 2 is incorrect because the Trade Margin Rationalisation was applied to 137 non-scheduled anti-cancer drugs, not scheduled formulations. Statement 3 is correct as the effective date is 9 November 2026.
- Q3Medium
According to the news, how many non-scheduled anti-cancer drugs were brought under the Trade Margin Rationalisation (TMR) by the NPPA?
Explanation: The article explicitly states that on October 17, the NPPA announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs. 543 is the total number of drug brands with revised MRPs.
- Q4Medium
What is a key criticism raised by health experts regarding the Trade Margin Rationalisation (TMR) policy for cancer drugs, as per the article?
Explanation: The article quotes Jan Swasthya Abhiyan stating that excluding medicines supplied free under Patient Assistance Programmes (PAPs) from TMR calculations has limited its potential impact on patients. This is a direct criticism mentioned in the text.
Frequently asked questions
1. What is the full form of NPPA?
National Pharmaceutical Pricing Authority
2. What is the parent Ministry of NPPA?
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
3. What is the number of drug brands revised?
543
4. What is the effective date for new prices?
9 November 2026
5. What is the non-scheduled drugs under TMR?
137
6. What is the example?
Price of Palbociclib: Fell from ~₹40,421 to ~₹2,720 per pack
7. What is the example?
Price of Thiotepa: Fell from ~₹80,072 to ~₹7,150 per vial
8. What is the current context?
NPPA released revised list on 28 October 2026 to address excessive trade margins in cancer drugs.
All sources
- Original28 October 2026 · Read story
